McGuire Investment Group LLC Buys Shares of 26,905 Altimmune, Inc. (NASDAQ:ALT)

Share on StockTwits

McGuire Investment Group LLC bought a new position in Altimmune, Inc. (NASDAQ:ALT) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 26,905 shares of the company’s stock, valued at approximately $303,000. McGuire Investment Group LLC owned about 0.08% of Altimmune at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of ALT. Sphera Funds Management LTD. bought a new stake in shares of Altimmune in the 3rd quarter valued at approximately $3,208,000. Charles Schwab Investment Management Inc. acquired a new stake in Altimmune in the third quarter valued at approximately $1,569,000. Cubist Systematic Strategies LLC bought a new stake in Altimmune in the third quarter worth approximately $970,000. California Public Employees Retirement System acquired a new position in shares of Altimmune during the 3rd quarter worth $776,000. Finally, Wells Fargo & Company MN raised its holdings in shares of Altimmune by 19,031.3% during the 3rd quarter. Wells Fargo & Company MN now owns 55,098 shares of the company’s stock valued at $727,000 after purchasing an additional 54,810 shares in the last quarter. 66.22% of the stock is owned by institutional investors.

In related news, Director Klaus Schafer sold 10,150 shares of the firm’s stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $9.91, for a total value of $100,586.50. Following the transaction, the director now owns 6,900 shares in the company, valued at $68,379. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Philip Hodges sold 2,500 shares of Altimmune stock in a transaction dated Monday, November 30th. The stock was sold at an average price of $12.00, for a total value of $30,000.00. Following the completion of the sale, the director now owns 14,731 shares of the company’s stock, valued at $176,772. The disclosure for this sale can be found here. 2.70% of the stock is currently owned by corporate insiders.

Shares of ALT traded down $0.16 on Wednesday, hitting $13.69. The company’s stock had a trading volume of 840,267 shares, compared to its average volume of 1,369,158. The company has a 50 day moving average price of $11.96 and a 200 day moving average price of $11.47. Altimmune, Inc. has a fifty-two week low of $1.60 and a fifty-two week high of $35.10. The company has a market capitalization of $452.74 million, a PE ratio of -6.92 and a beta of 1.51.

Altimmune (NASDAQ:ALT) last announced its earnings results on Monday, November 9th. The company reported ($0.54) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.92) by $0.38. The company had revenue of $2.94 million during the quarter, compared to analyst estimates of $0.73 million. Altimmune had a negative return on equity of 46.39% and a negative net margin of 659.33%. On average, research analysts predict that Altimmune, Inc. will post -2.61 earnings per share for the current fiscal year.

ALT has been the topic of several analyst reports. Evercore ISI reissued an “outperform” rating and set a $25.00 target price on shares of Altimmune in a research report on Tuesday, November 24th. B. Riley cut their price objective on Altimmune from $31.00 to $28.00 and set a “buy” rating on the stock in a research note on Thursday, November 12th. Zacks Investment Research raised Altimmune from a “sell” rating to a “hold” rating in a research report on Tuesday, October 13th. BidaskClub raised shares of Altimmune from a “strong sell” rating to a “sell” rating in a research report on Friday, November 6th. Finally, Jefferies Financial Group assumed coverage on Altimmune in a research note on Monday, December 14th. They issued a “buy” rating and a $25.00 price objective on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. Altimmune currently has an average rating of “Buy” and a consensus price target of $22.75.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focused developing treatments for liver disease, immune modulating therapies, and vaccines. The company develops HepTcell, an immunotherapeutic product candidate that has completed Phase I clinical trial for patients chronically infected with the hepatitis B virus; NasoShield, an anthrax vaccine to provide for protection after a single intranasal administration; NasoVAX, a recombinant intranasal vaccine product candidate; and AdCOVID, a single-dose intranasal vaccine to protect against COVID-19 Its preclinical stage products include ALT-801, a novel peptide-based dual GLP-1/Glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis; and ALT-702, an investigational tumor immunostimulant for treating cancer.

Featured Article: What is Green Investing?

Want to see what other hedge funds are holding ALT? Visit to get the latest 13F filings and insider trades for Altimmune, Inc. (NASDAQ:ALT).

Institutional Ownership by Quarter for Altimmune (NASDAQ:ALT)

Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with's FREE daily email newsletter.